Publications by authors named "Jay Gibbons"

Claim this Profile
U
Upregulation of MAPK Negative Feedback Regulators and RET in Mutant ALK Neuroblastoma: Implications for Targeted Treatment.
Irina Lambertz, Candy Kumps, Shana Claeys, Sven Lindner, Anneleen Beckers, Jay Gibbons

Clin Cancer Res· July 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Antitumor efficacy profile of PKI-402, a dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor.
Robert Mallon, Irwin Hollander, Larry Feldberg, Judy Lucas, Veronica Soloveva, Jay Gibbons

Mol Cancer Ther· April 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Novel imidazolopyrimidines as dual PI3-Kinase/mTOR inhibitors.
Aranapakam M Venkatesan, Christoph M Dehnhardt, Zecheng Chen, Efren Delos Santos, Osvaldo Dos Santos, Jay Gibbons

Bioorg Med Chem Lett· January 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Lead optimization of N-3-substituted 7-morpholinotriazolopyrimidines as dual phosphoinositide 3-kinase/mammalian target of rapamycin inhibitors: discovery of PKI-402.
Christoph M Dehnhardt, Aranapakam M Venkatesan, Efren Delos Santos, Zecheng Chen, Osvaldo Santos, Jay Gibbons

J Med Chem· January 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prognostic relevance of the mTOR pathway in renal cell carcinoma: implications for molecular patient selection for targeted therapy.
Allan J Pantuck, David B Seligson, Tobias Klatte, Hong Yu, John T Leppert, Jay Gibbons

Cancer· June 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phaeosphaeride A, an inhibitor of STAT3-dependent signaling isolated from an endophytic fungus.
Katherine N Maloney, Wenshan Hao, Jun Xu, Jay Gibbons, John Hucul

Org Lett· August 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
In vivo antitumor effects of the mTOR inhibitor CCI-779 against human multiple myeloma cells in a xenograft model.
Patrick Frost, Farhad Moatamed, Bao Hoang, Yijiang Shi, Joseph Gera, Jay Gibbons

Blood· December 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Characterization of (2R, 3S)-2-([[4-(2-butynyloxy)phenyl]sulfonyl]amino)-N,3-dihydroxybutanamide, a potent and selective inhibitor of TNF-alpha converting enzyme.
Yuhua Zhang, Martin Hegen, Jun Xu, James C Keith, Guixian Jin, Jay Gibbons

Int Immunopharmacol· December 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Identification and characterization of 4-[[4-(2-butynyloxy)phenyl]sulfonyl]-N-hydroxy-2,2-dimethyl-(3S)thiomorpholinecarboxamide (TMI-1), a novel dual tumor necrosis factor-alpha-converting enzyme/matrix metalloprotease inhibitor for the treatment of rheumatoid arthritis.
Yuhua Zhang, Jun Xu, Jeremy Levin, Martin Hegen, Guangde Li, Jay Gibbons

J Pharmacol Exp Ther· April 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis